MMPOWER-2 crossover trial
Treatment difference in 6MWT was 19.8 m (P=.0833); selected patient-reported fatigue measures showed signals.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Primary mitochondrial myopathy
n=30
Treatment difference in 6MWT was 19.8 m (P=.0833); selected patient-reported fatigue measures showed signals.
Small crossover study; primary functional difference was not statistically significant.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Treatment difference in 6MWT was 19.8 m (P=.0833); selected patient-reported fatigue measures showed signals.